Search

Your search keyword '"DeMicco, David A."' showing total 201 results
Start Over Author "DeMicco, David A." Language english
201 results on '"DeMicco, David A."'

1. Abstract 12482: Practical Adherence to AHA/ACC 2018 Guidelines Among Secondary Prevention Patients

Author

Kainat, Aleesha, Alish, Yousef, Ateya, Mohammad, Becich, Michael J, Bradley, Alison, Demicco, David A, Fernandez, Soledad, Ford, Dan, Hegeman-Dingle, Rozelle, Hwang, Wenke, Jeong, Jong, Jurczak, Martha O, Kirchner, H Lester, McLeod, Euan, McTigue, Kathleen M, Morgan, Richard S, Paranjape, Anuradha, Saccone, Phillip, Thomas, Neena, Townsend, Kevin A, Williams, David A, and Arnold, Jonathan

Published
2022
Full Text
View/download PDF

4. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk

Author

Arsenault, Benoit J., Petrides, Francine, Tabet, Fatiha, Bao, Weihang, Hovingh, G. Kees, Boekholdt, S. Matthijs, Ramin-Mangata, Stéphane, Meilhac, Olivier, DeMicco, David, Rye, Kerry-Anne, Waters, David D., Kastelein, John J.P., Barter, Philip, and Lambert, Gilles

Published
2018
Full Text
View/download PDF

16. Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial

Author

Soedamah-Muthu, Sabita S., Livingstone, Shona J., Charlton-Menys, Valentine, Betteridge, D. John, Hitman, Graham A., Neil, H. Andrew W., Bao, Weihang, DeMicco, David A., Preston, Gregory M., Fuller, John H., Stehouwer, Coen D. A., Schalkwijk, Casper G., Durrington, Paul N., Colhoun, Helen M., and on behalf of the CARDS Investigators

Published
2015
Full Text
View/download PDF

27. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories:The SPARCL Trial

Author

Szarek, Michael, Amarenco, Pierre, Callahan, Alfred, DeMicco, David, Fayyad, Rana, Goldstein, Larry B., Laskey, Rachel, Sillesen, Henrik, and Welch, K. Michael

Subjects
total events, transient ischemic attack, cardiovascular diseases, atorvastatin, stroke
Abstract

Background: In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, atorvastatin was compared with placebo in 4,731 participants with recent stroke or transient ischemic attack and no known coronary heart disease. Atorvastatin reduced the first occurrence of stroke and the first occurrence of a composite of vascular events. Objectives: The aim of this post hoc analysis was to assess the occurrence of all (first and subsequent) vascular events and the effect of atorvastatin to reduce these events by vascular territory (cerebrovascular, coronary, or peripheral) in SPARCL. Methods: Treatment effects on total adjudicated vascular events, overall and by vascular territory, were summarized by marginal proportional hazards models. Vascular event rates were estimated for each treatment group with cumulative incidence functions. Results: The placebo group had an estimated 41.2 first and 62.7 total vascular events per 100 participants over 6 years. There were 164 fewer first and 390 fewer total vascular events in the atorvastatin group (total events hazard ratio: 0.68; 95% confidence interval: 0.60 to 0.77). The total events reduction included 177 fewer cerebrovascular, 170 fewer coronary, and 43 fewer peripheral events. Over 6 years, an estimated 20 vascular events per 100 participants were avoided with atorvastatin treatment. Conclusions: In participants with recent stroke or transient ischemic attack, the total number of vascular events prevented with atorvastatin was more than twice the number of first events prevented. Total event reduction provides a comprehensive metric to capture the totality of atorvastatin clinical efficacy in reducing disease burden after stroke or transient ischemic attack. (Lipitor in the Prevention of Stroke, for Patients Who Have Had a Previous Stroke [SPARCL]; NCT00147602)

Published
2020

30. Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis

Author

Preiss, David, Tikkanen, Matti J., Welsh, Paul, Ford, Ian, Lovato, Laura C., Elam, Marshall B., LaRosa, John C., DeMicco, David A., Colhoun, Helen M., Goldenberg, Ilan, Murphy, Michael J., MacDonald, Thomas M., Pedersen, Terje R., Keech, Anthony C., Ridker, Paul M, Kjekshus, John, Sattar, Naveed, and McMurray, John J.

Published
2012
Full Text
View/download PDF

31. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis

Author

Boekholdt, S. Matthijs, Arsenault, Benoit J., Mora, Samia, Pedersen, Terje R., LaRosa, John C., Nestel, Paul J., Simes, R. John, Durrington, Paul, Hitman, Graham A., Welch, K. M., DeMicco, David A., Zwinderman, Aeilko H., Clearfield, Michael B., Downs, John R., Tonkin, Andrew M., Colhoun, Helen M., Gotto, Antonio M., Jr, Ridker, Paul M, and Kastelein, John J.

Published
2012
Full Text
View/download PDF

32. Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes: An Analysis From the CARDS Trial

Author

Colhoun, Helen M., Betteridge, D. John, Durrington, Paul, Hitman, Graham, Neil, Andrew, Livingstone, Shona, Charlton-Menys, Valentine, Bao, Weihang, DeMicco, David A., Preston, Gregory M., Deshmukh, Harshal, Tan, Kathryn, and Fuller, John H.

Published
2011
Full Text
View/download PDF

33. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis

Author

Preiss, David, Seshasai, Sreenivasa Rao, Welsh, Paul, Murphy, Sabina A., Ho, Jennifer E., Waters, David D., DeMicco, David A., Barter, Philip, Cannon, Christopher P., Sabatine, Marc S., Braunwald, Eugene, Kastelein, John J., de Lemos, James A., Blazing, Michael A., Pedersen, Terje R., Tikkanen, Matti J., Sattar, Naveed, and Ray, Kausik K.

Published
2011
Full Text
View/download PDF

38. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)

Author

Niel, H. Andrew W., DeMicco, David A., Luo, Don, Betteridge, D. John, Colhoun, Helen M., Durrington, Paul N., Livingstone, Shona J., Fuller, John H., and Hitman, Graham A.

Subjects
Statins -- Health aspects, Cardiovascular diseases -- Risk factors -- Drug therapy, Type 2 diabetes -- Risk factors -- Drug therapy, Health, Drug therapy, Risk factors, Health aspects
Abstract

OBJECTIVE- Rates of cardiovascular disease are highest in the elderly. Lipid-lowering statin therapy reduces the proportional risk as effectively in older patients as in younger individuals; however, limited data are [...]

Published
2006

41. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers

Author

Arsenault, Benoit J, Barter, Philip, DeMicco, David A, Bao, Weihang, Preston, Gregory M, LaRosa, John C, Grundy, Scott M, Deedwania, Prakash, Greten, Heiner, Wenger, Nanette K, Shepherd, James, Waters, David D, Kastelein, John JP, Treating to New Targets (TNT) Investigators, ACS - Amsterdam Cardiovascular Sciences, Vascular Medicine, and Berger, Jeffrey S

Subjects
Male, Time Factors, Physiology, Epidemiology, Atorvastatin, lcsh:Medicine, Coronary Disease, Coronary Artery Disease, Cardiovascular Physiology, Pathology and Laboratory Medicine, Cardiovascular, Biochemistry, Vascular Medicine, Gastroenterology, chemistry.chemical_compound, Medicine and Health Sciences, Molecular Targeted Therapy, Myocardial infarction, lcsh:Science, Immune Response, education.field_of_study, Multidisciplinary, Neopterin, Middle Aged, Prognosis, Lipids, Heart Disease, Research Design, 6.1 Pharmaceuticals, Blood Circulation, Female, lipids (amino acids, peptides, and proteins), Anatomy, Research Article, medicine.drug, medicine.medical_specialty, Drug Research and Development, Statin, Clinical Research Design, General Science & Technology, medicine.drug_class, Immunology, Clinical Trials and Supportive Activities, Population, Cardiology, Research and Analysis Methods, Treating to New Targets (TNT) Investigators, Diagnostic Medicine, Clinical Research, Diabetes mellitus, Internal medicine, medicine, Humans, cardiovascular diseases, education, Cardiovascular Disease Epidemiology, Heart Disease - Coronary Heart Disease, Inflammation, Pharmacology, Adiponectin, Cholesterol, business.industry, Pharmacoepidemiology, Prevention, lcsh:R, Immunity, Biology and Life Sciences, Evaluation of treatments and therapeutic interventions, Atherosclerosis, medicine.disease, Biomarker Epidemiology, Endocrinology, chemistry, Cardiovascular Anatomy, Clinical Immunology, lcsh:Q, Clinical Medicine, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Biomarkers
Abstract

Several plasma non-lipid biomarkers have been shown to predict major cardiovascular events (MCVEs) in population studies. Our objective was to investigate the relationship between lipid and non-lipid biomarkers levels achieved during statin therapy and the incidence of MCVEs in patients with stable coronary heart disease (CHD). We conducted a substudy of the TNT (Treating to New Targets) study, which was a randomized trial that compared the efficacy of high (80 mg) versus low (10 mg) dose atorvastatin for the secondary prevention of CHD. Fasting plasma levels of standard lipids and of 18 non-lipid biomarkers were obtained after an 8-week run-in period on atorvastatin 10 mg in 157 patients who experienced MCVEs during the 4.9 years of study follow-up and in 1349 controls. MCVE was defined as CHD death, nonfatal, non-procedure-related myocardial infarction, resuscitated cardiac arrest, and fatal or nonfatal stroke. After adjusting for age, sex and treatment arm, plasma levels of high-density lipoprotein (HDL) cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), insulin, neopterin, N-terminal pro-brain natriuretic peptide (BNP), lipoprotein(a) [Lp(a)], and the soluble receptor for advanced glycation end products (sRAGE) were predictive - 2014 Arsenault et al. This Funding: This study was funded by Pfizer Inc. Benoit J. Arsenault is supported by a post-doctoral fellowship from the Fonds de la recherche en santé du Québec and the Fondation de l9Institut universitaire de cardiologie et de pneumologie de Québec. Two authors are Pfizer employees and may hold stock in the company. As sponsor, Pfizer in cooperation with the steering committee had a role in all aspects of the study. The secondary biomarker analysis was funded by Pfizer. However, the decision to publish and preparation of the manuscript was driven solely by the authors. of recurrent MCVEs (P#0.02 for each doubling of plasma concentration). However, no significant association was observed between the risk of recurrent MCVEs and plasma levels of low-density lipoprotein cholesterol, adiponectin, cystatin C, lipoprotein-associated phospholipase A2, monocyte chemotactic protein-1, matrix metalloproteinase-9, myeloperoxidase, osteopontin, soluble CD40 ligand, soluble intercellular adhesion molecule-1, or soluble vascular cell adhesion molecule-1. After further adjustment for diabetes, hypertension, smoking, and BMI, the relationship between hsCRP, insulin and MCVE were no longer significant, while the relationship between Lp(a), neopterin, NT-proBNP and sRAGE and MCVE remained statistically significant. In conclusion, in patients with CHD treated with atorvastatin, plasma levels of Lp(a), neopterin, NT-proBNP, and sRAGE are associated with the risk of recurrent MCVEs.

Published
2014

46. Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial (Retracted article. See vol. 61, pg. 1751, 2013)

Author

Huijgen, Roeland, Boekholdt, S. Matthijs, Arsenault, Benoit J., Bao, Weihang, Davaine, Jean-Michel, Tabet, Fatiha, Petrides, Francine, Rye, Kerry-Anne, Demicco, David A., Barter, Philip J., Kastelein, John J. P., Lambert, Gilles, Other departments, Amsterdam Cardiovascular Sciences, Cardiology, and Vascular Medicine

Subjects
lipids (amino acids, peptides, and proteins)
Abstract

Objectives The purpose of this study was to investigate whether high levels of circulating proprotein convertase subtilisin kexin type 9 (PCSK9) would increase cardiovascular risk in statin-treated patients. Background Statins activate low-density lipoprotein (LDL) receptor gene expression, thus lowering plasma LDL levels. But statins also activate the expression of PCSK9, a secreted inhibitor of the LDL receptor, thereby limiting their beneficial effects. Methods We have measured the plasma PCSK9 levels of 1,613 patients with stable coronary heart disease enrolled in the Treating to New Targets study, a randomized trial that compared the efficacy of high-versus low-dose atorvastatin. After a run-in period with atorvastatin 10 mg daily, patients were randomized to either continue with 10 mg or be up-titrated to 80 mg of atorvastatin, and followed during 5 years for major cardiovascular events (MCVEs). Results Circulating PCSK9 levels measured at randomization were predictive of clinical outcomes in the group randomized to remain on atorvastatin 10 mg (p = 0.039), but not in the group that intensified atorvastatin treatment to 80 mg (p = 0.24). Further, PCSK9 levels measured 1 year post-randomization did not change upon increase of the statin dose. Conclusions PCSK9 levels predict cardiovascular events in patients treated with low-dose atorvastatin. (A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [TNT]; NCT00327691) (J Am Coll Cardiol 2012;59:1778-84) (C) 2012 by the American College of Cardiology Foundation

Published
2012

47. Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers.

Author

Arsenault, Benoit J., Barter, Philip, DeMicco, David A., Bao, Weihang, Preston, Gregory M., LaRosa, John C., Grundy, Scott M., Deedwania, Prakash, Greten, Heiner, Wenger, Nanette K., Shepherd, James, Waters, David D., Kastelein, John J. P., and null, null

Subjects
CARDIOVASCULAR agents, CORONARY disease, STATINS (Cardiovascular agents), RANDOMIZED controlled trials, LIPIDS, BIOMARKERS, PATIENTS
Abstract

: Several plasma non-lipid biomarkers have been shown to predict major cardiovascular events (MCVEs) in population studies. Our objective was to investigate the relationship between lipid and non-lipid biomarkers levels achieved during statin therapy and the incidence of MCVEs in patients with stable coronary heart disease (CHD). We conducted a substudy of the TNT (Treating to New Targets) study, which was a randomized trial that compared the efficacy of high (80 mg) versus low (10 mg) dose atorvastatin for the secondary prevention of CHD. Fasting plasma levels of standard lipids and of 18 non-lipid biomarkers were obtained after an 8-week run-in period on atorvastatin 10 mg in 157 patients who experienced MCVEs during the 4.9 years of study follow-up and in 1349 controls. MCVE was defined as CHD death, nonfatal, non-procedure-related myocardial infarction, resuscitated cardiac arrest, and fatal or nonfatal stroke. After adjusting for age, sex and treatment arm, plasma levels of high-density lipoprotein (HDL) cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), insulin, neopterin, N-terminal pro-brain natriuretic peptide (BNP), lipoprotein(a) [Lp(a)], and the soluble receptor for advanced glycation end products (sRAGE) were predictive of recurrent MCVEs (P≤0.02 for each doubling of plasma concentration). However, no significant association was observed between the risk of recurrent MCVEs and plasma levels of low-density lipoprotein cholesterol, adiponectin, cystatin C, lipoprotein-associated phospholipase A2, monocyte chemotactic protein-1, matrix metalloproteinase-9, myeloperoxidase, osteopontin, soluble CD40 ligand, soluble intercellular adhesion molecule-1, or soluble vascular cell adhesion molecule-1. After further adjustment for diabetes, hypertension, smoking, and BMI, the relationship between hsCRP, insulin and MCVE were no longer significant, while the relationship between Lp(a), neopterin, NT-proBNP and sRAGE and MCVE remained statistically significant. In conclusion, in patients with CHD treated with atorvastatin, plasma levels of Lp(a), neopterin, NT-proBNP, and sRAGE are associated with the risk of recurrent MCVEs. Trial Registration: ClinicalTrials.gov . [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results